2025 · 3rd Quarter (July 1 - Sep 30)

HEMATOLOGY ONCOLOGY PHARMACY ASSOCIATION

Filed by CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C..

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 15, 2025
Income: $50,000.00
Expenses: Not reported
Registrant: CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.
Client: HEMATOLOGY ONCOLOGY PHARMACY ASSOCIATION
Filing UUID: 33c815ec-54a4-4ed3-abd4-2d608e7eb7ec
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

FY25 and FY26 Labor HHS and Related Agencies

HCR · Health Issues

HR 4101, The Cancer Drug Parity Act; HR 3521, the Clinical Trials Moderization Act; Drug Shortages

Literal federal measure citations: HR 4101, HR 3521

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.